-
HR of 0.17! Tech-Dara: A Potent BCMA/CD38 Dual-Targeting Immunotherapy Combination Leads a New Paradigm in Second-Line MM Treatment—MAJEStec-3 Study Heavily Released
At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. María-Victoria Mateos, representing the research team, unveiled the highly anticipated results of the MAJEStec-3 study. This marks the first reported Phase III clinical trial of a BCMA-targeted bispecific antibody. Comparing the combination of Teclistamab and Daratumumab (“Tech-Dara”) against…
-
80% Reduction in Risk of Disease Progression or Death! Stunning Head-to-Head Phase III Data of Pirtobrutinib in First-Line CLL/SLL
At the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Sklodowska-Curie National Research Institute of Oncology (Poland) presented the highly anticipated results of a global Phase III clinical trial. This study is the first head-to-head comparison evaluating the efficacy and safety of the non-covalent BTK inhibitor, pirtobrutinib, against the…
-
Breaking Ex Vivo Limitations: In Vivo Gene Delivery CAR-T Therapy (KLN-1010) Achieves 100% MRD Negativity in RRMM Patients Without Lymphodepletion
At the 67th American Society of Hematology (ASH) Annual Meeting in 2025, a groundbreaking Late-Breaking Abstract (LBA) presented by Professor Phoebe Joy Ho (Royal Prince Alfred Hospital, Australia) signaled a potential paradigm shift in the treatment of multiple myeloma. The preliminary results from the Phase 1 inMMyCAR study of KLN-1010—the first in vivo anti-BCMA CAR-T…
-
Prof. Hanny Al-Samkari on the VEHIT-2 Phase III ITP Trial
In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses…
-
ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices
Lymphoma diagnosis and treatment are entering a phase of accelerated evolution, with breakthrough therapies and innovative research continuously reshaping clinical practice. From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando. At this year’s congress, multidimensional and in-depth innovations emerged across both aggressive…
-
Professor Zhang Yonghong: Two Decades of Transformation in Precision Diagnosis and Treatment of Pediatric Lymphoma in China
For many years, the treatment of pediatric lymphoma has been challenged by marked variability in therapeutic response and poor outcomes in relapsed or refractory cases. Under the leadership of Professor Zhang Yonghong, his team has driven the development of standardized and precision-based treatment strategies through long-term research and clinical innovation. In particular, they have achieved…
-
58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer
At the recent ESMO-ASIA Congress, Professor Takayuki delivered an in-depth interpretation of the latest follow-up data from the Asian subgroup of the KEYNOTE-859 study. The presentation explored the long-term clinical value of pembrolizumab plus chemotherapy as a first-line treatment for Asian patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, providing a comprehensive look at…
-
ASH 2025 | Prof. Jeff Sharman on Mosunetuzumab and Treatment Advances Beyond R-CHOP
At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in…
Connecting Medical Expertise through Media